CYH's volume growth faces pressure from softer elective procedures and payer mix, while a recovery in demand could help margins and cash flow.
THC's revenue growth persists despite softer surgical volumes, driven by higher revenue per case, acuity and favorable service mix.
HCA Healthcare's healthy volume growth faces payer-mix pressure, but cost controls, network expansion and Medicaid payments may support earnings growth.
Nutex Health's profitability and growth metrics significantly outpace peers, driven by effective use of the No Surprises Act and disciplined cost controls. See why NUTX stock is a Buy.
HCA Healthcare (HCA) is back in focus after five affiliated Texas hospitals filed suit against Independence Blue Cross, alleging more than $345,000 in unpaid claims between 2022 and 2024. At a share p
Analysts initiated bullish coverage on HCA, GRDN, TTC, MRVL and PLSE, setting price targets of $495, $52, $120, $270 and $70.
BMO Capital analyst Sean Dodge initiates coverage on HCA Healthcare (NYSE:HCA) with a Outperform rating and announces Price Target of $495.
View interactive chart, options flow, and AI analysis for HCA on Zorveq Finance.
Open HCA Chart & Analysis →